Showing 2241-2250 of 2314 results for "".
- Alcon Introduces New Medical Affairs Website in North America, Expanding Support for Patient Care and Clinical Communityhttps://modernod.com/news/alcon-introduces-new-medical-affairs-website-in-north-america-expanding-support-for-patient-care-and-clinical-community/2476149/Alcon recently launched a new website, AlconScience.com, for US- and Canada-based eye care professionals and academic institutions. The new medical affairs website consolidates information about Alcon’s scientific, academic, and related activities into one portal. Visitors may download clinically
- Coburn Technologies Introduces New Portable Slit Lamp to Product Linehttps://modernod.com/news/coburn-technologies-introduces-new-portable-slit-lamp-to-product-line/2479625/Coburn Technologies has introduced a new portable slit lamp to their diagnostics product line – the SK-LS-1B. The SK-LS-1B can be used in ophthalmology, optometry, and veterinary practices. With its hand-held operation, users are able to examine patients who don’t have ability or cannot si
- Takeda Shareholders Back Shire Purchasehttps://modernod.com/news/takeda-shareholders-back-shire-purchase/2479627/Shareholders of Japanese pharmaceutical company Takeda overwhelmingly voted in favor of acquiring UK-based Shire. The deal, currently valued at about $58 billion dollars, makes Takeda a top 10 global drugmaker by sales. Takeda shareholders on Wednesday voted 88 percent in favor in of thee
- FDA Approves Genentech’s ACTPen, the Actemra Autoinjector, for Giant Cell Arteritis, Other Indicationshttps://modernod.com/news/fda-approves-genentechs-actpen-the-actemra-autoinjector-for-giant-cell-arteritis-other-indications/2479647/Genentech announced that the FDA has approved ACTPen 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra (tocilizumab), as an additional formulation for adult patients with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-m
- Ophthotech Announces Results from Phase 2a Safety Trial of Zimura in Combination with Lucentis in Wet AMDhttps://modernod.com/news/ophthotech-announces-results-from-phase-2a-safety-trial-of-zimura-in-combination-with-lucentis-in-wet-amd/2479673/Ophthotech announced the results from its phase 2a safety trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). This trial was designed to evaluate the safety of different dosage regimens of Zimura combinat
- Acucela Initiates Phase 3 Study of Emixustat Addressing Patients with Stargardt Diseasehttps://modernod.com/news/acucela-initiates-phase-3-study-of-emixustat-addressing-patients-with-stargardt-disease/2479674/Acucela announced that on November 7, 2018, the first patient has enrolled in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride (emixustat), in subjects with macular atrophy secondary to Stargardt disease. The study is a multicenter, randomized, double-masked, a
- $4 Million Gift to Aid Construction of a Public Museum Dedicated to Vision and Eye Healthhttps://modernod.com/news/aao-announces-4-million-gift-to-aid-construction-of-a-public-museum-dedicated-to-vision-and-eye-health/2479720/The American Academy of Ophthalmology announced a project to construct the world’s first public museum dedicated to vision and eye health. The new museum will be located in San Francisco. Prominent ophthalmologist Stanley M. Truhlsen, MD, launched the project with a $4 million donation. The annou
- ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticalshttps://modernod.com/news/proqr-in-licenses-worldwide-rights-to-ophthalmology-drug-candidate-from-ionis-pharmaceuticals/2479723/ProQR Therapeutics announced the signing of an agreement with Ionis Pharmaceuticals to license QR-1123 (formerly IONIS-RHO-2.5Rx), an RNA medicine for autosomal dominant retinitis pigmentosa (adRP) caused by the P23H mutation in the rhodopsin (RHO) gene. “Building on th
- New STAIRWAY Study Data Shows Potential for Extended Durability with Faricimab in Wet AMDhttps://modernod.com/news/new-stairway-study-data-shows-potential-for-extended-durability-with-faricimab-in-wet-amd/2479728/Genentech announced positive results from the phase 2 STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD). At 52 weeks, faricimab patients dosed either every 16 weeks or every 12 weeks demonstrated sustained vi
- First Patient Screened in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitishttps://modernod.com/news/first-patient-screened-in-mallinckrodt-phase-4-trial-of-h-p-acthar-gel-for-severe-noninfectious-intermediate-uveitis-posterior-uveitis-or-panuveitis/2479736/Mallinckrodt confirmed screening of the first patient in the company’s phase 4, multicenter, multiple-dose, open label study to assess the effects of H.P. Acthar Gel as